Categories AlphaGraphs, Earnings, Other Industries
Earnings preview: What to look for when Medtronic reports Q1 2020 results
Medtronic plc (NYSE: MDT) is scheduled to report first quarter 2020 earnings results on Tuesday, August 20, before the opening bell. Analysts expect the company to report earnings of $1.18 per share on revenue of $7.4 billion.
This compares to revenues of $7.3 billion and adjusted earnings of $1.17 per share reported in the first quarter of 2019.
The company has been seeing revenue declines in its Cardiac and Vascular Group for the past few quarters. Revenues in the Diabetes Group also saw a drop last quarter. The performance of these segments will be an area to watch. The Minimally Invasive Therapies Group and the Restorative Therapies Group have posted revenue growth consistently over the past couple of quarters and this trend can be expected to continue in the first quarter.
During the first quarter, Medtronic completed the acquisition of Titan Spine and updates on this topic will be noteworthy. The acquisition will help further Medtronic’s strategy to transform spinal procedures and improve outcomes. The deal is expected to be immaterial to fiscal year 2020 adjusted EPS.
Also see: Medtronic Q4 2019 Earnings Conference Call Transcript
The company has also entered into various partnerships in order to improve and diversify its product offerings and updates on this area will be worth noting.
In the fourth quarter of 2019, Medtronic topped market expectations for revenue and earnings. Worldwide revenue was flat at $8.1 billion on a reported basis but rose 3.6% on an organic basis. Adjusted EPS grew 8% to $1.54. Revenues grew in the single digits range in the US and emerging markets but declined in non-US developed markets.
For fiscal year 2020, Medtronic has guided for organic revenue growth of 4% and adjusted EPS in the range of $5.44-5.50.
Shares of Medtronic have gained 13% thus far this year and 2% in the past one month. The majority of analysts have rated the stock as Buy and the average 12-month price target is $107.08.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on